Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV000193426 | SCV000246809 | uncertain significance | not specified | 2015-07-16 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000792908 | SCV000932235 | likely benign | Hereditary breast ovarian cancer syndrome | 2024-11-26 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003278689 | SCV004005420 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-04-19 | criteria provided, single submitter | clinical testing | The c.8953+5delG intronic variant, located in intron 21 of the BRCA2 gene, results from a deletion of one nucleotide within intron 21 of the BRCA2 gene. This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will not have any significant effect on splicing. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |